CoChat

A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults

Leroux-Roels, Isabel, Leroux-Roels, Geert, Clement, Frédéric, Vandepapelière, Pierre, Vassilev, Ventzislav, Ledent, Edouard, Heineman, Thomas C. · 2012 · The Journal of Infectious Diseases

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: An adjuvanted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of herpes zoster and its complications. METHODS: In a phase I/II, open-label, randomized, parallel-group study, older adults (50-70 years) received 2 doses 2 months apart of an adjuvanted recombinant glycoprotein E vaccine (HZ/su; n = 45), a live attenuated Oka strain VZV vaccine (OKA; n = 45), or HZ/su and OKA administered concomitantly (n = 45). To evaluate safety prior to administration in older adults, young adults (18-30 years) were vaccinated with 2 doses 2 months apart of HZ/su (n = 10) or OKA (n = 10). Safety and immunogenicity were assessed up to 42 months for older adults immunized with HZ/su and up to 12 months for all others. RESULTS: Few grade 3 events and no severe adverse events were reported. Fatigue, myalgia, headache, and injection site pain were the most common solicited reactions for HZ/su and occurred more frequently than with OKA. CD4(+) T-cell and humoral immune responses were much higher with HZ/su than with OKA and remained elevated until 42 months. Addition of OKA to HZ/su did not increase immunogenicity. CONCLUSIONS: In this study, HZ/su adjuvanted subunit vaccine was well tolerated and more immunogenic than a live attenuated VZV vaccine. Clinical Trial registration. NCT00492648 and NCT00492648.

Overview

Integrity signals

Registry

Crossref · 10.1093/infdis/jis497

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 147

Metadata

Authors
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C.
Affiliations
  • Ghent University Hospital (BE)
  • Neovacs (France) (FR)
  • GlaxoSmithKline (Belgium) (BE)
  • GlaxoSmithKline (United States) (US)
Venue
The Journal of Infectious Diseases
Published
2012-08-07
Volume
206
Issue
8
Pages
1280-1290
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2141655221
Cited by
147
References
34
Citations by year
2026: 4 · 2025: 11 · 2024: 9 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 9 · 2019: 15 · 2018: 19 · 2017: 15 · 2016: 16 · 2015: 12 · 2014: 9 · 2013: 8 · 2012: 1
FWCI
7.16
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
varicella-zoster virus, herpes zoster prevention, vaccine safety, immunogenicity, older adults, young adults, CD4+ T cell responses, humoral immune response, vaccine adverse events
MeSH terms
Adjuvants, Immunologic, Adolescent, Adult, Aged, Antibodies, Viral, Female, Glycoproteins, Herpes Zoster, Humans, Male, Middle Aged, Vaccination, Herpesvirus 3, Human, CD4-Positive T-Lymphocytes, Viral Structural Proteins, Chickenpox Vaccine, Vaccines, Subunit, Young Adult, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults. https://app.cochat.ai/papers/10.1093/infdis/jis497
The paper
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012). A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jis497

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.